Moving combination immunotherapy into the neoadjuvant setting for patients with stage III melanoma induces a higher rate of pathologic response than adjuvant therapy, said Christian U. Blank, MD, PhD, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, ÂAmsterdam, at the 2019 ASCO-ÂSITC Clinical Immuno-Oncology Symposium.
Dr Kaufman is the Chief Surgical Officer and Associate Director for Clinical Science at Rutgers Cancer Institute of New Jersey. He is a leading authority on tumor immunotherapy for the treatment of melanoma and has published more than 400 peer-reviewed scientific papers, books, review articles, and abstracts. He serves on [ Read More ]
An estimated 76,380 new cases of melanoma will be diagnosed in 2016, with an estimated 10,130 dying of this disease. Incidence rates for melanoma have increased steadily over the past several decades. In fact, in the United States, melanoma now has the 5th and 7th highest incidence for all cancers [ Read More ]
The standard of care for patients with advanced-stage melanoma has shifted from empiric treatment with chemotherapy that has low response rates to targeted therapy with response rates that are substantially higher, and immunotherapy, which has shown the most durable disease control. Chemotherapy is not intrinsically able to differentiate between tumor [ Read More ]
According to Steven O’Day, MD, Professor of Medical Oncology, The John Wayne Cancer Institute, Santa Monica, CA, the essential arguments supporting combinations of checkpoint blockade immunotherapy as the standard for treating metastatic melanoma arise out of their high disease control rates, rapid deep responses, improved response rates, longer progression-free survival, [ Read More ]
Rather than establishing a clear winner, a debate (“Intralesional Monotherapy: Is There a Role?â€) at the HemOnc Today Melanoma and Cutaneous Malignancies conference confirmed the words of Sanjiv S. Agarwala, MD, the meeting’s chairman and moderator: “Intralesional therapy is here to stay.†Roles for intraÂlesional therapy as either monotherapy or [ Read More ]
In 3 phase 1 and 2 studies, improved overall response rates (ORRs) were shown in patients with metastatic melanoma taking pembrolizumab (Keytruda) in combination with 3 other immunotherapies, including epaÂcadostat, talimogene laherparepvec (Imlygic), and ipiÂlimumab (Yervoy). All 3 studies demonstrated significant antitumor activity. In addition, long-term follow-up data in a [ Read More ]
Among patients with advanced melanoma treated with immunotherapies, those whose tumors had NRAS mutations had better response and treatment outcomes than those whose tumors did not, according to new research. Douglas B. Johnson, MD, and colleagues determined that 28% of patients with NRAS-mutant melanoma had complete or partial responses to [ Read More ]
On September 4, 2014, the FDA approved pembrolizumab for use in advanced or unresectable melanoma following progression on prior therapies. This approval was based on clinical data from the phase 1b KEYNOTE-001 trial and made pembrolizumab the first anti–PD-1 antibody to gain approval in the United States for any solid [ Read More ]
Overview Melanoma cases make up nearly 5% of new cancers diagnosed in the United States, making it the fifth most common type of cancer in this country.1 With the introduction of targeted therapy, melanoma treatment has undergone rapid changes in recent years, resulting in an overall 5-year survival rate of [ Read More ]
